Business
Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference
WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m. ET.\nA live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.\nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] Tel 212.600.1902\nMedia ContactBenjamin [email protected] Tel 862.368.4464\nSNDX-G\n View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-b-riley-securities-2022-oncology-conference-301464483.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":3184,"tagName":"div"}]